Stay updated on TERN-201 Safety and Efficacy in NASH Clinical Trial
Sign up to get notified when there's something new on the TERN-201 Safety and Efficacy in NASH Clinical Trial page.

Latest updates to the TERN-201 Safety and Efficacy in NASH Clinical Trial page
- Check4 days agoChange DetectedThe page now displays Revision: v3.6.6 instead of v3.6.5, indicating a software/template update to the page rather than changes to the study data.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedExplicit sponsor attribution now names Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), replacing the previous shorter form. The page revision has been updated to v3.6.5.SummaryDifference0.4%

- Check40 days agoChange DetectedThe page revision label has been updated to v3.6.4, indicating a newer version of the page content. The previous revision label v3.6.3 has been removed.SummaryDifference0.1%

- Check47 days agoChange DetectedTerminology for liver disease in the study's conditions has been updated from Fatty Liver Disease to Steatotic Liver Disease, aligning with current nomenclature.SummaryDifference0.1%

- Check61 days agoChange DetectedFooter revision tag updated from v3.6.2 to v3.6.3, signaling a new iteration of the page rendering. This reflects routine maintenance/version update and does not alter the study content.SummaryDifference0.1%

- Check68 days agoChange DetectedThe page's revision metadata updated from v3.6.0 to v3.6.2, representing a minor behind-the-scenes update that does not change the publicly visible study details.SummaryDifference0.1%

Stay in the know with updates to TERN-201 Safety and Efficacy in NASH Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TERN-201 Safety and Efficacy in NASH Clinical Trial page.